Table 3. Cumulative incidence and subhazards of death between Wave 1 and Wave 2 and mortality rate and Cox model hazard of death with remdesivir and dexamethasone.

	Wave 1	Wave 2
Entire period
Number of patients	1,215	2614
Number of deaths	317	351
28-day mortality rate (%, 95% CI)	26.1 (23.6–28.5)	13.1 (11.8–14.4)
Competing risk model
Unadjusted SHR	Ref	0.47 (0.40, 0.54) †
Fully adjusted (imputed) SHR	Ref	0.49 (0.37, 0.65) †
	No Remdesivir	Remdesivir
Entire period
Number of patients	3053	896
Number of deaths	571	114
28-day mortality rate (%)	18.7 (17.2–20.3)	12.7 (10.5–15.3)
Cox model unadjusted HR	Ref	0.64 (0.53, 0.79) †
Cox model propensity imputed HR*	Ref	0.84 (0.65, 1.08)
Limited to wave 2
Number of patients	1777	837
Number of deaths	244	107
28-day mortality rate (%)	13.7 (12.1–15.6)	12.4 (10.5–15.4)
Cox model unadjusted HR	Ref	0.91 (0.73, 1.14)
Cox model propensity imputed HR*	Ref	1.23 (0.94, 1.62)
	No Dexamethasone	Dexamethasone
Entire period
Number of patients	2032	1917
Number of deaths	384	301
28-day mortality rate (%)	18.9 (17.1–20.1)	15.7 (14.0–17.6)
Cox model unadjusted HR	Ref	0.80 (0.69, 0.93) #
Cox model propensity imputed HR*	Ref	0.97 (0.70, 1.35)
Limited to wave 2
Number of patients	745	1869
Number of deaths	60	291
28-day mortality rate (%)	8.1 (6.1–10.4)	15.6 (13.8–17.5)
Cox model unadjusted HR	Ref	1.99 (1.50, 2.62) †
Cox model propensity imputed HR*	Ref	1.05 (0.69, 1.59)

P values ^† = <0.001.

* Adjusted age, sex, ethnicity, hypertension, diabetes obesity and baseline physiological observation score, CRP, neutrophil, chest x-ray abnormality, remdesivir and dexamethasone. P values † = <0.001

* Adjusted age, sex, ethnicity, hypertension, diabetes obesity and baseline physiological observation score, CRP, Neutrophil, chest x-ray abnormality, remdesivir and dexamethasone.